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Abstract: The paper explored the regulatory role of oligodeoxynucleotides (ODNs) with 
specific sequences in the proliferation and activation of osteoblast, using human osteoblast-
like cell line MG 63 as the model. Through the administration of ODNs to MG 63 cells at a 
concentration  of  1.0  µ g/mL,  ODN  MT01  with  positive  effects  on  proliferation  and 
activation  of  osteoblast  was  selected  from  11  different  ODNs  by  methyl  thiazolyl 
tetrazolium (MTT) assay and alkaline phosphatase (ALP) activity measurement. To get 
a deeper  insight  into  the  molecular  mechanism,  effects  of  ODN  MT01  treatment  on 
the expression  level  of  Sp7,  runx-2,  collagen-I,  osteoprotegerin  (OPG)  and  RANK 
ligand (RANKL) were determined using quantitative real time PCR and Western blotting. 
Remarkably, the mRNA and protein expression levels of Sp7, runx-2, collagen-I and OPG 
were improved after ODN MT01 treatment. Meanwhile, the protein expression level of 
RANKL  was  dramatically  decreased.  These  results  suggested  that  ODN  MT01  had  a 
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significant impact in facilitating osteogenic proliferation and activation, and provided a 
direct evidence for the notion that single strand ODN could regulate the balance of bone 
formation and resorption, and thus was of great potential in the rebuilding of alveolar bone.  
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1. Introduction 
Orthodontic tooth movement is closely related to the remodeling of alveolar bone, and alveolar 
bone loss always occurs during orthodontic tooth movement, especially in patients with periodontal 
disease [1,2]. In addition, the loose and even loss of teeth caused by periodontal disease affects quality 
of life, even to the extent of forming edentulous jaw. For the edentulous patients with severe alveolar 
bone absorption, good retention and aesthetics could not be achieved only by dentures. Therefore, the 
regeneration of alveolar bone is of great significance in oral medicine research.  
In physiological conditions, the bone remodeling process is controlled by a complex network of 
endocrine hormones and local cytokines [3,4]. Two types of cells are involved in bone remodeling: 
osteoclasts originating from hematopoietic cells are responsible for bone resorption, and osteoblasts 
originating from mesenchymal cells are responsible for the formation of new bone [5]. Generally, the 
regeneration of alveolar bone processes as follows: growth factor-inducing bone marrow mesenchymal 
stem cells or periodontal ligament stem cells differentiate into osteoblast, which then synthesizes the 
mineralized  bone  matrix,  and  ultimately  induces  the  formation  of  bone  in  a  complex  biological 
route [6]. Over the past few years, research on alveolar bone regeneration has been greatly developed 
from the general tissue and cell levels to protein and gene levels [7,8]. With the development of 
alveolar surgery, molecular biology and tissue engineering, more and more new technology has been 
used for the repair and regeneration of alveolar bone defects, such as distraction osteogenesis [9,10], 
guided bone regeneration membrane [11], and application of growth factors [12,13]. Since osteoblast 
is directly associated with the synthesis of mineralized bone matrix, the proliferation and activation of 
osteoblast using growth factors and other agents will be an attractive issue in the alveolar bone repair 
and regeneration.  
Oligodeoxynucleotide (ODN) is one kind of the unmethylated nucleotide core motif sequences, 
which are unusual in mammalian genomes but prevalent in prokaryotes. It can also be obtained from 
the  DNA  degradation  products,  and  even  synthesized  and  modified  in  an  artificial  way.  It  is 
usually absorbed by cells in an endocytic manner, and then activates the pathway involving Toll-like 
receptor-9 (TLR9) [14]. Recent studies have found that specific ODN could regulate the formation and 
activation of osteoclasts [15–17]. Amcheslavsky et al. reported the effects of ODN on two types of 
mice osteoclast precursor cells (rich in TLR9 and TLR9 deficient, respectively), and concluded that 
ODN  played  a  key  role  in  regulating  the  formation  and  differentiation  of  osteoclast  in  a  TLR9 
dependent manner [16]. Chang et al. proved that the recognition of ODN CpG-KSK13 via TLR9 could 
inhibit  the  osteoclastogenesis  by  down-regulating  the  expression  of  TREM-2  [17].  In  2003, 
Penolazzi et al. found that a specific sequence of ODN could counteract nuclear factor-κB (NF-κB) to 
promote the osteoclast apoptosis and inhibit the early differentiation of osteoclast [15]. The receptor Int. J. Mol. Sci. 2011, 12                       
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activators  of  NF-κB (RANK), RANK ligand  (RANKL)  and  osteoprotegerin  (OPG), constitute the 
essential  regulatory  components  in  the  paracrine  signaling  necessary  for  osteoclast  differentiation, 
activation and apoptosis, which has been considered as a connection pathway between osteoblast and 
osteoclastogenesis  [18].  Previous  research  showed  that  CpG  ODNs  could  modulate  the 
osteoclastogenesis in bone marrow cell/osteoblast co-cultures [19]. As the osteoblast could express the 
receptor TLR9, upon TLR9 ligation, the RANKL expression level was improved in osteoblast, and 
could be inhibited by chloroquine, which proved that CpG ODNs induced the osteoclastogenic activity 
in osteoblast in a RANKL-dependent pattern [19]. However, the effects of ODNs on the activation and 
proliferation of osteoblast have not been clearly elucidated.  
In the present research, we designed and synthesized 11 ODNs of different sequences, and those 
that  could  promote  the  proliferation  of  osteoblast-like  cell  line  MG  63  were  screened  by  methyl 
thiazolyl  tetrazolium  (MTT)  assay.  Then  the  ODNs  with  the  ability  to  promote  osteoblastic 
proliferation and activation were selected by the detection of alkaline phosphatase (ALP) expression 
level. Using real time PCR and Western blotting analysis, effects of ODNs on the expression level of 
Sp7,  runx-2,  collagen-I,  OPG  and  RANKL  were  investigated  to  get  a  deeper  insight  into  the  
molecular mechanism.  
2. Results and Discussion 
2.1. MTT Assay 
In the present research, we first investigated the effects of 11 different ODNs on the cell viability 
and proliferation of MG63 osteoblast-like cells using MTT assay (Figure 1). It was shown that the 
OD495 values of cells co-cultured with ODN BW001, ODN FC002, ODN MT01, ODN YW001 were 
higher than the control group. After 72 h, compared with the control, the values increased by 15.9%, 
23.7%, 25.4% and 19.8%, respectively (P < 0.05). Similar tendency was observed for other treatment 
time (data not shown). The results indicated that the proliferation efficiency were highly associated 
with the sequence, and ODN BW001, ODN FC002, ODN MT01 and ODN YW001 could efficiently 
promote the early proliferation of MG 63 cells in this research.  
Previous reports have shown that ODNs could be absorbed into cells through the receptor-mediated 
pathway without constructing a vector, and applied for evaluating the curative effect on treatment 
mastitis, allergic rhinitis and conjunctivitis in pre-clinical studies. In addition, specific ODNs could 
regulate  the  osteoclast  differentiation  through  different  signaling  pathways  [20,21].  Herein,  we 
modified  all  the  ODNs  via  phosphorothioic  acid  to  enhance  their  cellular  uptake  capability  and 
stability. The above results showed that ODNs of specific sequences could influence the proliferation 
of  osteoblast  and  further  regulate  the  osteoblast-osteoclast  balance  through  different  signaling 
pathways, which provided a potential way for regulating bone rebuilding using ODNs.  
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Figure 1. Effects of 11 different ODNs on the cell viability and proliferation of MG 63 
osteoblast-like cells after 72 h treatment. *Statistically significant difference (P < 0.05) 
between experimental and control groups.  
 
2.2. Effect of ODNs on ALP Activity 
To  assess  the  effect  of  ODNs  on  osteoblastic  activation,  MG  63  cells  were  treated  with  five 
ODNs (ODN BW001, ODN FC002, ODN BW006, ODN MT01 and ODN YW001) at a concentration 
of 1.0 µ g/mL, which have been screened from the MTT assay, and then the activities of osteoblast-related 
marker  ALP  were  assessed.  As  shown  in  Figure  2,  the  ALP  activities  were  associated  with  the 
sequence of ODNs and treatment time. At 24 h, the experimental groups of ODN FC002, ODN MT01, 
ODN YW001 significantly induced ALP activity in MG 63 (P < 0.05). However, after 48 h and 72 h 
treatment, there were no statistically significant differences between the experimental groups (ODN 
FC002 and ODN YW001) and control group. However, the ALP activities were remarkably improved 
compared to the control group after ODN MT01 treatment, with statistically significant differences at 
24 h, 48 h and 72 h (P < 0.05).  
To date, most research associated with ODN focused on the CG-rich motif ODN (CpG ODN). 
Recently, Zou et al. found that CpG ODN could regulate the osteoclast formation and differentiation in 
TLR9 dependent individual through TLR9-mediated molecular pathway [19]. CpG ODN could inhibit 
the  osteoclast  differentiation  by  upregulating  the  expression  of  IL-12  to  inhibit  RANKL,  which 
suggested its potential in preventing the possibility of pathological bone resorption [22]. However, 
there  are  no  previous  reports  that  ODNs  with  no  CpG  motif  had  effects  on  the  activation  and 
proliferation of osteoblasts. In this paper, using MTT and ALP assay, we first obtained the no CpG 
ODNs with promising activity for promoting the proliferation and activation of MG 63 cells, and thus 
provided a novel way for the bone rebuilding research.  
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Figure 2. Effect of ODNs treatment on ALP activity of MG 63 cells, for different time 
intervals. *Statistically significant difference (P < 0.05) between experimental and control 
groups at the given time point.  
 
2.3. Effect of ODN MT01 on the Morphology of MG 63 Cells 
After treatment with 1.0 µ g/mL ODN MT01 for 72 h, we used an inverted microscope to evaluate 
the effect of ODN MT01 on the cellular morphology of MG 63. As shown in Figure 3, good growth 
state was observed in both the ODN MT01-treated group and control group, which indicated that there 
were no adverse effects with ODN MT01 treatment.  
Figure 3. (A) MG 63 cells cultured in DMEM for 72 h; (B) MG 63 cells cultured in ODN 
MT01 (1.0 µ g/mL)-DMEM for 72 h.  
 
 
2.4. Effect of ODN MT01 on Gene Expression of MG 63 Cells 
The above results have confirmed that ODN MT01 could efficiently promote the proliferation and 
activation of osteoblast. Afterwards, we detected the effects of ODN MT01 treatment on the mRNA 
level of bone-related factors Sp7, runx-2, and collagen-I, using quantitative real time PCR. As shown 
in Figure 4, compared with control group, mRNA levels of Sp7, runx-2 and collagen-I were increased 
in MG 63 cells after ODN MT01 treatment. For Sp7, significantly higher mRNA levels were observed 
at 24 h, 48 h and 96 h after ODN MT01 treatment (Figure 4A); for runx-2 mRNA level, it exhibited an Int. J. Mol. Sci. 2011, 12                       
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increasing tendency before 48 h and then slightly decreased (Figure 4B). Nevertheless, the collagen-I 
mRNA level was upregulated in the experimental group with the increase of culture time, and the 
values were much higher than those of control group after 72 h and 96 h treatment, which provided a 
direct evidence for the up-regulation of osteoblastic activity (Figure 4C).  
The transcription factor runx-2 has a well-defined role in mediating the final stages of osteoblastic 
maturation, and is necessary for the normal osteogenesis and usually upregulated during osteoblastic 
activity.  Runx-2  deficiency  or  mutation  could  cause  severe  bone  abnormalities  in  mouse  and 
human [23,24]. In runx-2 null mice, no endochondral or membranous bone was formed, due to an 
arrest during the early steps of osteoblast differentiation. Here, the mRNA level of runx-2 was greatly 
influenced by ODN MT01, and higher expression levels at 48 h and 72 h proved that ODN MT01 
could promote the early osteoblastic activation of MG 63 cells. Sp7, another transcription factor, was 
considered  as  the downstream of  runx-2, and  could served  as  an  inhibitor of chondrogenesis  and 
chondrocyte  maturation,  while  it  promoted  the  osteoblast  maturation  [25,26].  Meanwhile,  Sp7 
expression  was  up-regulated  by  BMP-2  in  a  runx-2-independent  pattern  [27].  The  above  results 
suggested Sp7 might function as a master regulator capable of converting non-osseous mesenchymal 
cells (e.g., fibroblasts) into cells committed to the osteogenic lineage (i.e., osteoblasts). In addition, 
Kim et al. demonstrated that the forced expression of Sp7 was not sufficient to convert non-osseous 
cells into osteoblastic cells, and promote full expression of the mature bone phenotype [28]. In our 
study, the results showed that ODN MT01 could significantly increase the mRNA level of Sp7, runx-2 
and  collagen-I  at  an  early  stage,  which  suggested  that  the  proliferation  and  activation  of  MG  63 
cells after  ODN  MT01  treatment  were  probably  attributed  to  the  abnormal  expression  of  these 
osteoblast-related factors. 
Figure 4. Real time PCR analysis of MG 63 cells of experimental group (ODN MT01 
treatment) and control group (PBS treatment) at predetermined time. (A) Relative amounts 
of mRNA for Sp7 were quantified and GAPDH was used as internal control; (B) Relative 
amounts of mRNA for runx-2 were quantified and GAPDH was used as internal control; 
(C) Relative amounts of mRNA for collagen-I were quantified and GAPDH was used as 
internal control. *Statistically significant difference (P < 0.05) between experimental and 
control groups (n = 3).  
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Figure 4. Cont. 
 
 
 
2.5. Western Blotting Analysis  
To get a further insight, MG 63 was treated with ODN MT01 (1.0 µ g/mL) for different time, the 
protein expression levels of Sp7, runx-2, collagen-I, OPG and RANKL were measured using Western 
blotting technique. As shown in Figure 5, compared with the control group, the protein expression 
levels of Sp7, runx-2 and collagen-I were obviously increased to a certain degree. Significantly higher 
expression levels of Sp7 were observed at 24 h and 48 h in the experimental group, and then decreased 
slightly at 72 h and increased at 96 h, which was consistent with real time PCR analysis. The protein 
expression levels of runx-2 were slightly increased from 24 to 96 h, and the collagen-I expression 
levels of the experimental group were significantly higher at 48 h and 96 h. Meanwhile, the OPG 
expression  levels  of  experimental  group  were  higher  at  48  h  and  72  h.  Nevertheless,  RANKL 
expression level was dramatically decreased.  
Bone  remodeling  is  tightly  regulated  by  a  molecular  triad  composed  of  OPG/RANK/RANKL, 
which has been considered as a connection pathway between osteoblast and osteoclastogenesis [29]. 
RANKL is mainly synthesized by the osteoblastic lineage cells, and is essential for mediating bone Int. J. Mol. Sci. 2011, 12                       
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resorption through mediating osteoclastogenesis and the activation of mature osteoclasts [29,30]. The 
Western blotting analysis suggested that ODN MT01 might promote the proliferation and activation of 
MG 63 cells via the increasing ratio of OPG expression level to RANKL. In the present study, the 
expression level of OPG was improved, while RANKL expression level was significantly decreased.  
Figure 5. Western blotting analysis of expression level of Sp7, runx-2, collagen-I, OPG 
and RANKL in ODN MT01 treatment group and control group at predetermined time.  
 
3. Experimental Section 
3.1. Materials 
ODNs were obtained from College of Molecular Biology in Jilin University (Table 1), and then 
dissolved in axenic phosphate buffered solution (PBS). According to the functional characteristics, 
these ODNs could be divided into three types: (1) immunostimulant, including BW001 [31], FC001, 
BW006  [32],  FC002,  YW001  [33],  FC004  and  YW002  [34];  (2)  immunosuppressant,  including 
SAT05f [35], MT01 [35] and FC003; (3) immunologic inertia, such as MS19 [34]. Among them, 
BW001, BW006, YW001, YW002, SAT05f, MT01 and MS19 were once reported in our previous 
research [31–35], and others were first employed in the present research.  
Human  osteoblast-like  cell  line  MG  63  was  obtained  from  American  Type  Culture 
Collection (ATCC, CRL-1427), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
and  dimethyl  sulphoxide  (DMSO)  were  purchased  from  Sigma-Aldrich  (St.  Louis,  MO,  USA). 
Alkaline phosphatase (ALP) kit and micro-BCA assay kit were obtained from Jiancheng Biological 
Reagent Co. (Nanjing, China). Real time PCR kit was purchased from TaKaRa (Tokyo, Japan). The 
monoclonal antibodies of anti β-actin, Sp7 and OPG were purchased from Santa Cruz Biotech. Co., 
and those of anti runx-2, collagen- I and RANKL were purchased from Abcam Co. (USA).  
3.2. Cell Culture 
The human MG 63 cell line was maintained in Dulbecco’s modified eagle’s medium (DMEM, 
Sigma,  ST.  Louis,  MO,  USA)  containing  10%  heat-inactivated  fetal  calf  serum,  100  units/mL Int. J. Mol. Sci. 2011, 12                       
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penicillin  and  100  mg/mL  streptomycin  at  37  ° C  in  a  5%  CO2  fully  humidified  incubator.  For 
subculture,  cells  at 80–90%  confluence were  passaged  at a ratio of 1:3 after  treating with 0.25% 
trypsin. When the cells (between 3th to 5th passage) have grown to semi-confluence, they were treated 
with different ODNs at a concentration of 1.0 µ g/mL for 24 h, 48 h, 72 h, and 96 h.  
Table 1. ODNs (11 different sequences) were used for co-culture with MG 63 cells to 
screen the ones that could improve the proliferation of cells.  
Number  Name  Sequence 
1  SAT05f  5'-CCTCCTCCTCCTCCTCCTCCTCCT-3' 
2  MS19  5'-AAAGAAAGAAAGAAAGAAAGAAAG-3' 
3  BW001  5'-TCGTCGGGTGCGACGTCGCAGGGGGG-3' 
4  FC001  5'-TCGGGGACGATCGTCGGGGAC-3' 
5  FC002  5'-TCGTCGACGTCGTCGTTCTC-3' 
6  BW006  5'-TCGACGTTCGTCGTTCGTCGTTC-3' 
7  YW002  5'-TCGCGAACGTTCGCCGCGTTCGAACGCGG-3' 
8  FC004  5'-TCGCGTTCGATCGCGATCGACGGTA-3' 
9  MT01  5'-ACCCCCTCTACCCCCTCTACCCCCTCT-3' 
10  YW001  5'-TCGCGACGTTCGCCCGACGTTCGGTA-3' 
11  FC003  5'-TCTCTCTCTCTCTCTCTCTCTCTC-3' 
3.3. MTT Assay 
All the MTT assays were carried out in 96-well plates. Briefly, wells with 5000 cells/well were 
filled with 100 µL DMEM and 10% fetal calf serum (FCS), and 11 different ODNs (Table 1) were 
added to each well at a final concentration of 1.0 µ g/mL. Control groups received no ODNs. The 
plates were incubated from 24 h to 96 h at 37 ° C. After a brief wash with medium, 10 µ L MTT 
(5 mg/mL) was added to each well, followed by incubation for additional 4 h. Finally, the supernatant 
was removed, and cells were lysed with 150 µL  DMSO. The absorbance at 495 nm of each well 
was measured  using  a  Bio  RAD  550  automatic  plate  reader.  The  values  were  the  average  of 
triplicate measurements.  
3.4. Measurement of ALP Activity 
After treating with ODNs (1.0 µ g/mL) for 24 h, 72 h and 120 h, cells were collected and lysed for 
ALP activity measurement. The experiment was conducted using Alkaline Phosphatase Kit, according 
to  the  manufacturer’s  instructions.  The  protein  concentration  of  cell  lysates  was  measured  using  
micro-BCA assay kit, and ALP activity was normalized for total protein concentration. The values 
were the average of triplicate measurements.  
3.5. Real-Time PCR 
Total  RNA  was  isolated  from  MG  63  cells  using  the  TRIzol  reagent  according  to  the 
manufacturer’s instructions. The purity of total RNA was determined by the ratio  at 260 nm and 
280 nm absorbance. 1 μg of total RNA was subjected to reverse transcription using RT-PCR Array 
First Strand Kit (SABioscience Co., USA). Following reverse transcription, each sample was diluted Int. J. Mol. Sci. 2011, 12                       
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so  that  cDNA  corresponding  to  the  produced  from  10  ng  of  total  RNA  was  used  in  subsequent  
real-time  PCRs. The primers  (Table  2)  were  designed  using qPrimerDepot,  a  primer database  for 
quantitative  real-time  PCR  and  subsequently  checked  for  specificity  using  BLAST 
(www.ncbi.nlm.nih.gov/genome/srq/HsBlast.html). PCRs were performed using the ABI Steponeplus 
(ABI PRISM, USA), which allowed real-time monitoring of the increase in PCR product concentration 
after every cycle based on the fluorescence of the double-stranded DNA specific dye SYBR green. The 
number of cycles required to produce a detectable product above background was measured for each 
sample. These cycle numbers were then used to calculate fold differences in starting mRNA level for 
each  sample  using  the  following  method.  First,  the  cycle  number  difference  for  GAPDH,  a 
housekeeping gene, was determined in the control sample and appropriate ODN-treated sample. The 
2
−∆∆CT method [36] was used for calculating the relative expression levels. The values were the average 
of triplicate measurements. 
Table 2. The primers used for qRT-PCR of various genes.  
Gene Name  Oligonucleotide UP (5’-3’)  Oligonucleotide DW (5’-3’) 
GAPDH  ATG GGG AAG GTG AAG GTC  TAA AAG CAG CCC TGG TGA CC 
SP7  CAC AGC TCT TCT GAC TGT CTG  CTG GTG AAA TGC CTG CAT GGA T 
RUNX-2  GAG ATC ATC GCC GAC CAC  TAC CTC TCC GAG GGC TAC C 
COLLAGEN-I  AGG GCC AAG ACG AAG ACA TC  AGA TCA CGT CAT CGC ACA ACA 
3.6. Western Blotting 
MG 63 cells were cultured in 10 cm double dish and treated with the ODN MT01 (1.0 µ g/mL) for 
predetermined  time.  Then  the  cells  were  collected,  washed  twice  with  Tris-buffered  saline,  and 
centrifuged at 5000 ×  g for 5 min at 4 ° C. Afterwards, the collected cells were suspended in lysis 
buffer (50 mM Tris, pH 7.6, 0.01% EDTA, 1% Triton X-100, 1 mM PMSF, and 1 µ g/mL leupeptin) on 
ice for 30 min, and centrifuged at 12000 ×  g for 15 min at 4 ° C. The protein concentration was 
measured using BCA Protein Assay Reagent kit. The samples (40 μg protein) were separated by 12% 
SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were 
blocked  with  5%  skim  milk  in  Tris-buffered  saline  with  0.1%  Tween  (TBST)  for  1  h  at  room 
temperature,  and  followed  by  incubation  with  primary  antibody  at  4  ° C  overnight.  Then  the 
membranes  were  incubated  with  secondary  antibody  at  20  °C   for  2  h,  and  detected  using  ECL 
chemiluminescent system. Loading differences were normalized using a monoclonal β-actin antibody. 
3.7. Statistical Analysis 
All experiments were performed on at least three individuals with each assay. The results were 
presented as mean ±  SD. Using the Student’s t-test to analyze the data concerning the differences of 
gene expression. One-way ANOVA was applied to analyze the data concerning the cell proliferation 
and ALP activity. (A probability level of 5%, P < 0.05 was considered statistically significant).  Int. J. Mol. Sci. 2011, 12                       
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4. Conclusions 
In  this  paper,  an  ODN  with  no  CpG,  ODN  MT01,  was  found  to  have  a  significant  effect  in 
facilitating osteogenic proliferation and activation, and this was probably due to the increasing ratio of 
OPG expression level to RANKL. This study provided a direct evidence for the notion that single 
strand ODN could regulate the balance of bone formation and resorption, and therefore has great 
potential in the rebuilding of alveolar bone.  
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